Emergent BioSolutions (EBS) EBIAT: 2010-2025
Historic EBIAT for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $51.2 million.
- Emergent BioSolutions' EBIAT fell 55.40% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 136.35%. This contributed to the annual value of -$190.6 million for FY2024, which is 74.94% up from last year.
- Emergent BioSolutions' EBIAT amounted to $51.2 million in Q3 2025, which was up 526.67% from -$12.0 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' EBIAT registered a high of $193.1 million during Q4 2021, and its lowest value of -$283.1 million during Q2 2024.
- Its 3-year average for EBIAT is -$76.7 million, with a median of -$31.3 million in 2024.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 10,480.00% in 2022, then soared by 655.56% in 2025.
- Quarterly analysis of 5 years shows Emergent BioSolutions' EBIAT stood at $193.1 million in 2021, then crashed by 134.70% to -$67.0 million in 2022, then grew by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then crashed by 55.40% to $51.2 million in 2025.
- Its EBIAT stands at $51.2 million for Q3 2025, versus -$12.0 million for Q2 2025 and $68.0 million for Q1 2025.